bioRxiv · 10.1101/2022.01.15.475214
Modulating CRISPR-Cas genome editing using guide-complementary DNA oligonucleotides
Abstract
CRISPR-Cas has revolutionized genome editing and has a great potential for applications, such as correcting human genetic disorders. To increase the safety of genome editing applications, CRISPR-Cas may benefit from strict control over Cas enzyme activity. Previously, anti-CRISPR proteins and designed oligonucleotides have been proposed to modulate CRISPR-Cas activity. Here we report on the potential of guide-complementary DNA oligonucleotides as controlled inhibitors of Cas9 ribonucleoprotein complexes. First, we show that DNA oligonucleotides down-regulate Cas9 activity in human cells, reducing both on and off-target cleavage. We then used in vitro assays to better understand how inhibition is achieved and under which conditions. Two factors were found to be important for robust inhibition: the length of the complementary region, and the presence of a PAM-loop on the inhibitor. We conclude that DNA oligonucleotides can be used to effectively inhibit Cas9 activity both ex vivo and in vitro.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Swartjes, T., Shang, P., van den Berg, D., Kunne, T. A., Geijsen, N., Brouns, S. J. J., van der Oost, J., Staals, R., Notebaart, R. A.. 2022-01-15. Modulating CRISPR-Cas genome editing using guide-complementary DNA oligonucleotides. https://doi.org/10.1101/2022.01.15.475214
Cite the original work for its findings. Save a collection to share your selection of sources.